Switch to doravirine/islatravir maintains viral suppression, safe in adults with HIV-1

17 giờ trước
Stephen Padilla
Stephen PadillaSenior Editor; MIMS
Stephen Padilla
Stephen Padilla Senior Editor; MIMS
Switch to doravirine/islatravir maintains viral suppression, safe in adults with HIV-1

Adults living with HIV-1 who have switched to doravirine/islatravir (100 mg/0.25 mg) demonstrate sustained virologic suppression and good tolerability to the new regimen at week 96, with consistent results across subgroups, as shown in two randomized, active-controlled phase III studies.

“Switching to doravirine/islatravir [once daily] was generally well tolerated across subgroups with no adverse effect on CD4+ T-cell or total lymphocyte counts,” said study co-author and presenter Dr Moti Ramgopal, Medical Director, Midway Immunology and Research Center, Fort Pierce, Florida, US.

A total of 708 participants switched to doravirine/islatravir on day 1 across the two studies (MK-8591A-051 [P051] and MK-8591A-052 [P052]). Of these, 50 percent were aged ≥50 years, 32 percent were women, 49 percent were White individuals, 39 percent were of Black or African American heritage, and 18 percent were Hispanic or Latinx. [Ramgopal, MN, et al, IDWeek 2026]

Overall, 90.8 percent of participants achieved viral suppression (HIV-1 RNA <50 copies/mL) at week 96. This was maintained at similar rates across subgroups based on age, sex assigned at birth, race, and ethnicity (range, 88.1 percent to 95.1 percent).

Safety profile

The proportion of participants who experienced any adverse event (AE), drug-related AEs, and discontinuations due to AEs were generally consistent across demographic subgroups at week 96 in the two phase III trials.

However, drug-related AEs were higher in P051 than P052 (50/366 [13.7 percent] vs 38/342 [11.1 percent]), “which may reflect the open-label design,” according to Ramgopal.

The most common drug-related AEs in P051 were diarrhoea (3.3 percent) and weight increase (2.2 percent). In P052, diarrhoea (1.5 percent) was also the most frequently reported drug-related AE, followed by decreased lymphocyte count (1.2 percent) and pruritus (1.2 percent).

The switch to doravirine/islatravir did not adversely affect CD4+ T-cell or total lymphocyte counts across subgroups. Overall, the mean percent change in CD4+ T-cell count was 6.0 percent (95 percent confidence interval [CI], 3.6‒8.3) at week 96 in the doravirine/islatravir group.

Weight change

In terms of weight, the mean change from baseline at week 96 in P051 was 0.94 kg (95 percent CI, 0.27‒1.61) with doravirine/islatravir compared with 2.99 (95 percent CI, 1.77‒4.20) with regimens containing efavirenz (EFV) and/or tenofovir disoproxil fumarate (TDF) and ‒0.13 kg (95 percent CI, ‒0.89 to 0.64) with no EFV/TDF.

“Mean weight increases were generally greater in those who switched from regimens containing EFV and/or TDF, although the pattern varied across demographic subgroups,” Ramgopal said.

In P052, the mean weight change from baseline at week 96 was 0.34 kg (95 percent CI, ‒0.38 to 1.06) with doravirine/islatravir compared with 0.42 kg (95 percent CI, ‒0.37 to 1.24) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), with a treatment difference of ‒0.03, 95 percent CI, ‒1.18 to 1.11).

“Mean changes in weight were not statistically significant across demographic factors,” Ramgopal said.

Study details

In the study, adults with HIV-1 RNA receiving stable oral baseline antiretroviral therapy (ART; P051; open label) or BIC/FTC/TAF (P052; double blind) for ≥3 months were randomly allocated 2:1 to switch to doravirine/islatravir or to continue their current regimen.

All participants in P051 received open-label doravirine/islatravir after week 48 through week 144. Only those who switched to doravirine/islatravir on day 1 were included in the current analysis.

Ramgopal and colleagues pooled the efficacy results and mean percent change from baseline in CD4+ T-cell and total lymphocyte counts for the doravirine/islatravir groups from both studies and summarized these by age, sex assigned at birth, race, and ethnicity at week 9. They also assessed AEs by demographic subgroup for each study separately due to the difference in study design.

“Doravirine/islatravir is a new single-tablet regimen containing doravirine 100 mg and islatravir 0.25 mg that is available in the US and Japan to replace the current ART regimen in adults living with HIV-1 who are virologically suppressed,” Ramgopal said.